

# Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

## PE/Dazzle(TM) 594 anti-human CD19

RRID:AB\_2563559

Type: Antibody

### Proper Citation

BioLegend Cat# 302251, RRID:AB\_2563559

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2563559](http://antibodyregistry.org/AB_2563559)

**Proper Citation:** BioLegend Cat# 302251, RRID:AB\_2563559

**Target Antigen:** CD19

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PE/Dazzle(TM) 594 anti-human CD19

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** Clone HIB19

**Antibody ID:** AB\_2563559

**Vendor:** BioLegend

**Catalog Number:** 302251

**Alternative Catalog Numbers:** 302252

**Record Creation Time:** 20250820T022839+0000

**Record Last Update:** 20250820T134137+0000

### Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-human CD19.

No alerts have been found for PE/Dazzle(TM) 594 anti-human CD19.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Poort VM, et al. (2024) Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation. Cancer research, 84(16), 2720.

Sutton MS, et al. (2023) Vaccine elicitation and structural basis for antibody protection against alphaviruses. Cell, 186(12), 2672.

Sagnella SM, et al. (2020) Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer cell, 37(3), 354.